CFDE Data Portal | Search LINC03020

	Label	Description
	LINC03020 Gene (Entity type)	ENSG00000253967 - long intergenic non-protein coding RNA 3020
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 4 v 14 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193838 catechin 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193838 catechin 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE153443 decitabine 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212057 SIRT6 overexpression 2 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC03020

ENSG00000253967 - long intergenic non-protein coding RNA 3020

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 4 v 14 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 4 human up

A Gene Set from LINCS

GSE193838 catechin 0 v 2 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 6 human up

A Gene Set from LINCS

GSE193838 catechin 0 v 4 human dn

A Gene Set from LINCS

GSE153443 decitabine 1 v 3 human up

A Gene Set from LINCS

GSE212057 SIRT6 overexpression 2 v 7 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.